| atezolizumab based treatment | nivolumab based treatment | anti-PD-(L)1 | pembrolizumab based treatment | sintilimab based treatment |
| atezolizumab plus bevacizumab | nivolumab alone | pembrolizumab based treatment | pembrolizumab alone | pembrolizumab plus lenvatinib | sintilimab |
mHCC - (neo)adjuvant (NA) | | | | | | |
mHCC - 1st line (L1) 4 | | | | | | |
mHCC - 2nd line (L2) 2 | | | | | | |